
Array Biopharma has revealed new data on its combination of Braftovi (encorafenib), Mektovi (binimetinib), and Erbitux (cetuximab), showing that it …

Braftovi (encorafenib), a BRAF kinase inhibitor developed by Pierre Fabre, has been awarded approval in combination with Mektovi (binimetinib) by …
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion

